U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
3681136811Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)AvailableNo Results AvailableMelanomaBiological: Pembrolizumabhttps://ClinicalTrials.gov/show/NCT02083484
3681236812Cow's Milk and Hen's Egg Hyposensitization in AdultsNot yet recruitingNo Results AvailableEgg Allergy|Cow's Milk AllergyDietary Supplement: Specific Oral Tolerance Induction with Egg or Cow's milkhttps://ClinicalTrials.gov/show/NCT02083471
3681336813An Infraclavicular Landmark-based Approach to the Axillary VeinCompletedNo Results AvailableCritical IllnessProcedure: Catheterization of the axillary vein.https://ClinicalTrials.gov/show/NCT02083458
3681436814Exercise, Hypoxia and CPC in TBI PatientsCompletedNo Results AvailableTraumatic Brain InjuryOther: cognitive activities|Other: Exercise program|Device: Muscle electro-stimulation|Other: Intermittent hypobaric hypoxiahttps://ClinicalTrials.gov/show/NCT02083445
3681536815Cognitive Behavioural Treatment of Intra-oral Injection-phobia in 10-16 Year Old Children and AdolescentsEnrolling by invitationNo Results AvailableDental AnxietyBehavioral: 5 session of CBT performed by specially trained dentistshttps://ClinicalTrials.gov/show/NCT02083432
3681636816Cardiac Resynchronization Therapy (CRT) and Left Ventricular Assist Devices (LVAD) TherapySuspendedNo Results AvailableHeart FailureDevice: LVAD CRThttps://ClinicalTrials.gov/show/NCT02083419
3681736817Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)CompletedHas ResultsMalariaDrug: 800mg OZ439 prototype formulation 1|Drug: 800mg OZ439 prototype formulation 2|Drug: 800mg OZ439 prototype formulation 3|Drug: 960mg PQPhttps://ClinicalTrials.gov/show/NCT02083406
3681836818Changes of Dendritic Cells in Acute Lung InjuryCompletedNo Results AvailableAcute Lung Injuryhttps://ClinicalTrials.gov/show/NCT02083393
3681936819Phase IIb Study to Investigate the Efficacy of OZ439 & Piperaquine Phosphate Co-administered to Adults & Children With Uncomplicated Plasmodium Falciparum.Active, not recruitingNo Results AvailableUncomplicated Plasmodium Falciparum MalariaDrug: A) OZ439 800mg: PQP 1440mg|Drug: B) OZ439 800mg: PQP 960mg|Drug: C) OZ439 800mg: PQP 640mghttps://ClinicalTrials.gov/show/NCT02083380
3682036820Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy OutcomeCompletedNo Results AvailableHepatic Encephalopathy|Cirrhosis|Nonalcoholic Steatohepatitis|Hepatitis Chttps://ClinicalTrials.gov/show/NCT02083367
3682136821Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 E/K Mutation-Positive Acral Lentiginous MelanomaRecruitingNo Results AvailableCancerDrug: Dabrafenib|Drug: Trametinibhttps://ClinicalTrials.gov/show/NCT02083354
3682236822Effects of External Vibration on Voice Quality in Muscle Tension Dysphonia Patients and Classically Trained SingersRecruitingNo Results AvailableDysphonia|SingingDevice: Lelo® Siri vibrator|Device: Lelo® Siri vibrator with vibration component removedhttps://ClinicalTrials.gov/show/NCT02083341
3682336823Influence of Caffeine on HRV and Exercise Performance in Spinal Cord InjuryCompletedNo Results AvailableCaffeine|Spinal Cord InjuryDietary Supplement: Caffeine|Dietary Supplement: Placebo (Mannitol)https://ClinicalTrials.gov/show/NCT02083328
3682436824Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy SubjectsCompletedNo Results AvailablePain, AcuteDrug: TRV130 1.5 mg|Drug: TRV130 3 mg|Drug: TRV130 4.5 mg|Drug: Morphine 10 mg|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02083315
3682536825Experimentally Testing the Effectiveness of a Campus-based Bystander InterventionCompletedNo Results AvailableAssaultive Behavior|Violence|Sexual Assault and Rape|Helping BehaviorBehavioral: SCREAM Theater Dose 1|Behavioral: SCREAM Theater Doses 2 & SCREAM Theater Dose 3|Behavioral: SCREAM Theater Dose 4https://ClinicalTrials.gov/show/NCT02083302
3682636826A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)CompletedNo Results AvailableOcular Hypertension|Open Angle-glaucomaDrug: ONO-9054|Drug: Latanoprosthttps://ClinicalTrials.gov/show/NCT02083289
3682736827Mecillinam for Treatment of Genital Chlamydia InfectionTerminatedNo Results AvailableChlamydia Trachomatis Infection|Chlamydial UrethritisDrug: Pivmecillinamhydrochloridhttps://ClinicalTrials.gov/show/NCT02083276
3682836828Non Invasive Ventilation as Airway Clearance in Patients With Cystic FibrosisCompletedHas ResultsCystic FibrosisDevice: Bilevel|Device: PEP maskhttps://ClinicalTrials.gov/show/NCT02083263
3682936829Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute LeukemiaRecruitingNo Results AvailableLeukemiaDrug: Fludarabine|Drug: Clofarabine|Drug: Busulfan|Drug: SAHA|Procedure: Stem Cell Infusion (SCT)|Drug: Thymoglobulinhttps://ClinicalTrials.gov/show/NCT02083250
3683036830Evaluation of an Intervention for Living With Mild Cognitive ImpairmentRecruitingNo Results AvailableMild Cognitive ImpairmentBehavioral: Behavioural Intervention Programhttps://ClinicalTrials.gov/show/NCT02083237
3683136831Familial Cancer Registry and DNA BankRecruitingNo Results AvailableCancerhttps://ClinicalTrials.gov/show/NCT02083224
3683236832Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical CarcinomaCompletedNo Results AvailableCervical Cancer Recurrent or Persistent|Palliative Treatment|Monoclonal Antibody in Cervical Cancer TreatmentDrug: mAb Nimotuzumab|Device: Placebohttps://ClinicalTrials.gov/show/NCT02083211
3683336833Effects of IV Chloride Content on OutcomesRecruitingNo Results AvailableSIRS|Balanced Fluids|Plasmalytehttps://ClinicalTrials.gov/show/NCT02083198
3683436834A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate CancerActive, not recruitingNo Results AvailableProstate CancerDrug: TAK-385, 80 mg|Drug: TAK-385, 120 mg|Drug: Leuprorelinhttps://ClinicalTrials.gov/show/NCT02083185
3683536835Comparing USCOM and Echocardiographic Hemodynamic Measurements in Children (CUE Study)RecruitingNo Results AvailableHemodynamically Stable|Critical IllnessDevice: Ultrasound Cardiac Output Monitor and 2 D-Echohttps://ClinicalTrials.gov/show/NCT02083172
3683636836C1q/TNF-related Proteins in Non-Alcoholic Fatty Liver DiseaseRecruitingNo Results AvailableNAFLDhttps://ClinicalTrials.gov/show/NCT02083159
3683736837C1q/TNF-related Proteins in Coronary Artery DiseaseRecruitingNo Results AvailableCoronary Artery Disease (CAD)https://ClinicalTrials.gov/show/NCT02083146
3683836838Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or HemodialysisEnrolling by invitationNo Results AvailableDiabetes|Hypoglycemia|Renal Dysfunction|Insulin Dosinghttps://ClinicalTrials.gov/show/NCT02083133
3683936839Efficacy and Physiology of Nasal High Flow TherapyRecruitingNo Results AvailablePulmonary Disease, Chronic ObstructiveDevice: NHF therapy|Other: Long term Oxygen Therapy (LOT)https://ClinicalTrials.gov/show/NCT02083120
3684036840Comparison Between Rectal & Sublingual Misoprostol Before Caesarian Section To Reduce Intra & Post-Operative Blood LossCompletedHas ResultsPostpartum HemorrhageDrug: Misoprostolhttps://ClinicalTrials.gov/show/NCT02083107

* Görseller ve İçerik tekif hakkına sahip olabilir